Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities Investment enables ten new J.MD™ projects encompassing molecular optimization including, but not limited to: improved titer, pharmacokinetics, immunogenicity, and stability, over the next three years HAMBURG, DE / ACCESS Newswire / January 8, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announces that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just - Evotec Biologics' molecular design suite of computational technologies, called "J.MD™". Investment (INV072135) continues the support for selected Gates Foundation grantees to improve the developability and reduce the cost of goods of monoclonal antibodies to make them more affordable and accessible and prevent infectious disease in low- and middle-income countries.